ICA Group Wealth Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-220
Closed -$92K 1323
2024
Q1
$92K Buy
220
+150
+214% +$63.4K 0.02% 416
2023
Q4
$28.5K Buy
+70
New +$25.9K 0.01% 635
2023
Q3
Sell
-37
Closed -$13K 1211
2023
Q2
$13K Buy
37
+5
+16% +$1.69K ﹤0.01% 789
2023
Q1
$10.1K Hold
32
﹤0.01% 808
2022
Q4
$9.24K Buy
+32
New +$9.75K ﹤0.01% 839

Other funds holding VRTX

ICA Group Wealth Management's VRTX Position: Q2 2024 in Review

ICA Group Wealth Management sold out of Vertex Pharmaceuticals (VRTX) in Q2 2024, closing a stake of 220 shares — an estimated $92K sold.

ICA Group Wealth Management first reported a position in VRTX in Q4 2022 and held it in 5 quarters. The position peaked at $92K in Q1 2024. 1,546 funds tracked by Wall St. Rank hold VRTX as of Q2 2024.

  • ICA Group Wealth Management reported no remaining Vertex Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • ICA Group Wealth Management sold 220 Vertex Pharmaceuticals shares in Q2 2024, an estimated $92K.
  • ICA Group Wealth Management first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 5 quarters.
  • ICA Group Wealth Management's Vertex Pharmaceuticals position peaked at $92K in Q1 2024.
  • 1,546 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2024.

Based on ICA Group Wealth Management's 13F filing for Q2 2024, filed 8 Aug 2024.